• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Treace Medical Concepts Inc.

    2/3/25 4:38:47 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care
    Get the next $TMCI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    TREACE MEDICAL CONCEPTS, INC.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    89455T109

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    89455T109


    1Names of Reporting Persons

    Morgan Stanley
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,074,734.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,091,809.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,091,809.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.4 %
    12Type of Reporting Person (See Instructions)

    HC, CO

    Comment for Type of Reporting Person:  As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    TREACE MEDICAL CONCEPTS, INC.
    (b)Address of issuer's principal executive offices:

    100 PALMETTO PARK PLACE, PONTE VEDRA FL 32081, UNITED STATES OF AMERICA
    Item 2. 
    (a)Name of person filing:

    Morgan Stanley
    (b)Address or principal business office or, if none, residence:

    1585 Broadway, New York, NY 10036
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    89455T109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the response(s) to Item 9 on the attached cover page(s).
    (b)Percent of class:

    3.4  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See the response(s) to Item 5 on the attached cover page(s).

     (ii) Shared power to vote or to direct the vote:

    See the response(s) to Item 6 on the attached cover page(s).

     (iii) Sole power to dispose or to direct the disposition of:

    See the response(s) to Item 7 on the attached cover page(s).

     (iv) Shared power to dispose or to direct the disposition of:

    See the response(s) to Item 8 on the attached cover page(s).

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Morgan Stanley
     
    Signature:Christopher O'Hara
    Name/Title:Authorized Signatory, Morgan Stanley
    Date:02/03/2025
    Get the next $TMCI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TMCI

    DatePrice TargetRatingAnalyst
    11/7/2025$5.00Neutral → Underweight
    Analyst
    11/7/2025Buy → Neutral
    BTIG Research
    2/4/2025$16.00Neutral → Buy
    BTIG Research
    12/31/2024$14.50Buy
    Lake Street
    12/17/2024$8.00Neutral
    Analyst
    5/16/2024$16.00 → $6.50Buy → Neutral
    UBS
    5/8/2024$15.00 → $5.50Overweight → Equal-Weight
    Morgan Stanley
    5/8/2024$17.00 → $7.00Buy → Hold
    Truist
    More analyst ratings

    $TMCI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Treace Medical Concepts Inc.

    SCHEDULE 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    2/12/26 5:57:53 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

    1/13/26 8:54:59 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

    12/18/25 8:44:09 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026

    PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the fourth quarter and full year of 2025 before the open of trading on Friday, February 27, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask qu

    2/12/26 5:13:32 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue

    PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced its preliminary, unaudited fourth quarter and full-year 2025 revenue results. Highlights: Preliminary revenue of $62.1 million to $62.5 million in the fourth quarter of 2025, an approximate 9% decrease at the midpoint over the same period in 2024.Preliminary revenue of $212.3 million to $212.7 million for the full-year 2025, an approximate 2% increase at the midpoint compared to the prior year and in-line with the previousl

    1/13/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Announces First Surgical Case Utilizing Lapiplasty® Lightning™ Technology

    PONTE VEDRA, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the successful completion of the first case utilizing its Lapiplasty® Lightning™ technology. Lightning technology expands upon Treace's market-leading Lapiplasty® System with advanced new instrumentation designed to reduce surgical steps, precisely correct in all three planes, and further streamline procedural workflow with Treace's SpeedPlate® Rapid Compression Fixation technology. "As the pioneers and leaders in instrumen

    1/8/26 4:05:00 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Treace John T. bought $524,064 worth of shares (60,000 units at $8.73), increasing direct ownership by 0.89% to 6,796,190 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    3/4/25 6:30:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Treace John T. bought $265,630 worth of shares (50,000 units at $5.31), increasing direct ownership by 0.77% to 6,523,095 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    9/17/24 5:17:19 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Director Treace James T bought $501,035 worth of shares (84,000 units at $5.96), increasing direct ownership by 7% to 1,223,441 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    8/19/24 9:00:08 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Treace Medical Concepts downgraded by Analyst with a new price target

    Analyst downgraded Treace Medical Concepts from Neutral to Underweight and set a new price target of $5.00

    11/7/25 8:29:21 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts downgraded by BTIG Research

    BTIG Research downgraded Treace Medical Concepts from Buy to Neutral

    11/7/25 8:29:10 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts upgraded by BTIG Research with a new price target

    BTIG Research upgraded Treace Medical Concepts from Neutral to Buy and set a new price target of $16.00

    2/4/25 7:10:07 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Innovation Officer Scanlan Sean F. exercised 16,875 shares at a strike of $1.05, increasing direct ownership by 2% to 706,474 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    2/11/26 9:00:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Innovation Officer Scanlan Sean F. exercised 53,500 shares at a strike of $0.72 and was granted 262,500 shares, increasing direct ownership by 85% to 689,599 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    1/23/26 9:30:05 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Treace John T. covered exercise/tax liability with 14,254 shares and was granted 250,000 shares, increasing direct ownership by 3% to 7,011,633 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    1/23/26 9:30:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Leadership Updates

    Live Leadership Updates

    View All

    Treace Appoints Guy Guglielmino as Chief Commercial Officer

    PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position, Mr. Guglielmino will lead Treace's commercial efforts and play a pivotal role in driving the Company's next phase of rapid innovation, strategic product commercialization, and growth. "I am thrilled to welcome Guy to the Treace team," said John T. Treace, CEO, Founder and B

    12/2/24 4:15:00 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts Appoints Nathan Minnich as Senior Vice President, Marketing

    PONTE VEDRA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced Nathan Minnich has been appointed Sr. Vice President, Marketing, effective immediately. In this new position, Mr. Minnich will lead all aspects of Treace's marketing efforts, with a focus on expanding the Company's physician outreach, patient awareness and market penetration efforts.  "I am delighted to welcome Nathan to the Treace team," said John T. Treace, CEO, Fou

    8/21/23 7:00:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Appoints Julie Dewey as Chief Communications and Investor Relations Officer

    PONTE VEDRA, Fla., July 12, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that Julie Dewey will join the Company as Chief Communications and Investor Relations Officer, effective July 17, 2023. In this new position, Ms. Dewey will lead all aspects of Treace's corporate communications and investor relations engagement, with a focus on expanding the company's outreach with the investment community and broadening the Company's relationships wit

    7/12/23 4:15:00 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Treace Medical Concepts Inc.

    SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    11/14/24 3:38:23 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Treace Medical Concepts Inc.

    SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    11/12/24 6:01:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Treace Medical Concepts Inc.

    SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    11/8/24 3:44:13 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $TMCI
    Financials

    Live finance-specific insights

    View All

    Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026

    PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the fourth quarter and full year of 2025 before the open of trading on Friday, February 27, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask qu

    2/12/26 5:13:32 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue

    PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced its preliminary, unaudited fourth quarter and full-year 2025 revenue results. Highlights: Preliminary revenue of $62.1 million to $62.5 million in the fourth quarter of 2025, an approximate 9% decrease at the midpoint over the same period in 2024.Preliminary revenue of $212.3 million to $212.7 million for the full-year 2025, an approximate 2% increase at the midpoint compared to the prior year and in-line with the previousl

    1/13/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Treace Medical Concepts Reports Third Quarter 2025 Financial Results

    PONTE VEDRA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights Generated revenue of $50.2 million in third quarter 2025 representing growth of 11% over the same period in 2024. Reported third quarter 2025 net loss of $(16.3) million and improved adjusted EBITDA by 49% to $(2.6) million in the third quarter 2025 compared to $(5.1) million in the same period in 2024.Presented clinical data at the American

    11/6/25 4:05:00 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care